The Expert panel of the Central drug regulator, DCGA will meet today to discuss grant of emergency use authorisation to the Sputnik-V Vaccine. The clinical trial of the vaccine in India is being done by Dr Reddy’s Lab. The Hyderabad based, multinational Indian pharma company, Dr. Reddy’s Lab has also inked an agreement with the Russian Direct Investment Fund, RDIF for supply of the Russian Sputnik V vaccine in India.
The Subject Expert Committee of the Indian drug regulator in its last meeting on 1st April had asked Dr Reddy’s to submit data on how the shot activates the body’s immune response against the coronavirus. RDIF has claimed an effectiveness of 91.6 per cent for the Sputnik V vaccine. Dr Reddy’s had applied for emergency use of Sputnik-V in February this year.
Upon approval, this will be the third vaccine to be used in India after Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin.
Support Ethical Journalism. Support The Dispatch
The Dispatch is a sincere effort in ethical journalism. Truth, Accuracy, Independence, Fairness, Impartiality, Humanity and Accountability are key elements of our editorial policy. But we are still not able to generate great stories, because we don’t have adequate resources. As more and more media falls into corporate and political control, informed citizens across the world are funding independent journalism initiatives. Here is your chance to support your local media startup and help independent journalism survive. Click the link below to make a payment of your choice and be a stakeholder in public spirited journalism